Print this page
-
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy.
Protocol: 042211Principal Investigator:
- Coral Omene MD, PhD (Rutgers University)
Applicable Disease Sites: Breast -
GS-US-592-6238-A Randomized, Open-Label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1.
Protocol: 042202Principal Investigator:
- Coral Omene MD, PhD (Rutgers University)
Applicable Disease Sites: Breast -
GS-US-592-6173-A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1.
Protocol: 042204Principal Investigator:
- Coral Omene MD, PhD (Rutgers University)
Applicable Disease Sites: Breast -
I-SPY 2 TRIAL: (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).
Protocol: 042102Principal Investigator:
- Coral Omene MD, PhD (Rutgers University)
Applicable Disease Sites: Breast -
A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib.
Protocol: 042106Principal Investigator:
- Coral Omene MD, PhD (Rutgers University)
Applicable Disease Sites: Breast